Two IPOs are scheduled to raise $1.3 billion in the week ahead. While the IPO calendar is relatively quiet at the moment, several issuers could launch, including pool equipment supplier Hayward Holdings (HAYW) and crafts-focused...read more
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised $221 million by offering 13.8 million shares at $16, the high end of the $14 to $16 range. Talis originally filed to sell 10 million shares, before...read more
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. The IPO pipeline remained active as well, with 3 IPOs and 38 SPACs submitting initial filings. ...read more
Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company previously planned to offer 7.8 million shares. At...read more
US IPO Week Ahead: Health insurer Oscar Health leads a 2 IPO week
Two IPOs are scheduled to raise $1.3 billion in the week ahead. While the IPO calendar is relatively quiet at the moment, several issuers could launch, including pool equipment supplier Hayward Holdings (HAYW) and crafts-focused...read more
COVID-19 test developer Talis Biomedical prices upsized IPO at $16 high end
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised $221 million by offering 13.8 million shares at $16, the high end of the $14 to $16 range. Talis originally filed to sell 10 million shares, before...read more
US IPO Weekly Recap: Biotechs flood the IPO market in a 14 IPO week
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. The IPO pipeline remained active as well, with 3 IPOs and 38 SPACs submitting initial filings. ...read more
COVID-19 test kit developer Lucira Health prices upsized IPO at $17 high end
Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company previously planned to offer 7.8 million shares. At...read more